Medindia

X

Cempra Pharmaceuticals To Present at the Lazard Capital Markets 6th Annual Healthcare Conference on November 17th

Saturday, November 14, 2009 General News J E 4
Advertisement


CHAPEL HILL, N.C., Nov. 13 Cempra Pharmaceuticals Inc. today announced that Prabhavathi Fernandes, president and chief executive officer, will present at the Lazard Capital Markets 6th Annual Healthcare Conference on November 17, 2009 at 9:25 a.m. EST at The St. Regis Hotel in New York City. Dr. Fernandes will provide an overview of the company's two leading antibiotic clinical programs for the treatment of drug-resistant pathogens including MRSA.

About Cempra Pharmaceuticals

Founded in 2006, Cempra Pharmaceuticals is a privately-held, clinical-stage biotechnology company focused on developing antibacterials to address critical medical needs. Two lead products, both in late-stage clinical trials, address the urgent and increasing need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. Cempra is well-funded and is committed to developing commercially viable products through consideration of pricing and reimbursement issues throughout its products' lifecycles. The company is also utilizing its proprietary chemistry technology to develop macrolides without antibacterial activity for non-antibiotic uses in motilin receptor activity, anti-inflammatory activity and GnRH receptor antagonism. Additional information about Cempra can be found at www.cempra.com.

Media Contacts: Robert E. Flamm, Ph.D. Russo Partners, LLC (212) 845-4226 Robert.flamm@russopartnersllc.com Tony Russo, Ph.D. Russo Partners, LLC (212) 845-4251 Tony.russo@russopartnersllc.com

SOURCE Cempra Pharmaceuticals Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Custom Spine Launches Pathway AVID and Regent ACP ...
S
Dr. Steven M. Paul to Retire from Lilly as Executi...